Intellectual Property Prospector

IP Assets Owned by Firms in Transition

April 16, 2007
Volume 2, Number 16

Prospector Profiles in this Issue

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
Raptor Networks Technology, Inc.	**07.0531**	Audit Concerns
Raser Technologies, Inc.	**07.0532**	Loss/Deficit
Remington Arms Company, Inc.	**07.0533**	Low Rating
Sabre Holdings Corporation	**07.0534**	Low Rating
SatCon Technology Corporation	**07.0535**	Audit Concerns
Securus Technologies, Inc.	**07.0536**	Loss/Deficit
SPO Medical, Inc.	**07.0537**	Audit Concerns
Synthron, Inc.	**07.0538**	Chapter 7 Sale
Targeted Genetics Corporation	**07.0539**	Audit Concerns
Thermadyne Holdings Corporation	**07.0540**	Low Rating
Thorium Power Limited	**07.0541**	Loss/Deficit
Transmeta Corporation	**07.0542**	Audit Concerns
Viking Systems, Inc.	**07.0543**	Audit Concerns
Web.com, Inc.	**07.0544**	Loss/Deficit
World Heart Corp.	**07.0545**	Audit Concerns
Zi Corporation	**07.0546**	Loss/Deficit

(Click on Reference Number to go directly to Company Profile)

Intellectual Property Prospector identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (http://BeardGroup.com). For subscription information call Customer Service at 240-629-3300, ext. 27.

Prospector Profile Selection Criteria:

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.

- Chapter 11, 7, or 15 bankruptcy filing

- Section 363 Sales

DISCLAIMER: The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

ACCURACY & COVERAGE: The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

SUBSCRIPTIONS: Subscription rate: $575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

Intellectual Property Prospector is a publication **of Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, http://www.beardgroup.com. ISSN 1935-3901. Copyright 2007. All rights reserved. Publisher: Christopher Beard.

Prospector Profile 07.0503

Advanced Life Sciences Holdings, Inc.

1440 Davey Road
Woodridge, IL 60517
630-739-6744

NAICS		541710
Employees		28
Revenue	(mil)	$0.04
Income	(mil)	($20.54)
Assets	(mil)	$30.51
Liability	(mil)	$9.12

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Deloitte & Touche LLP raised substantial doubt about the ability of Advanced Life Sciences Holdings, Inc. to continue as a going concern after auditing the Company's financial statements. The Company does not have sufficient cash on-hand or other funding available to meet its obligations and sustain its operations.

Intellectual Property: The Company has assembled a broad intellectual property portfolio encompassing the use, methods of preparation and methods of manufacture for product candidates in the areas of infectious disease, oncology and inflammation. The Company currently has exclusive access to 62 issued U.S. and international patents. In addition, 23 U.S. and international patent applications has been filed and are in various stages of processing. [SEC Filing 10-K 03-22-07]

Description: The Company engages in the discovery, development, and commercialization of drugs in the areas of infectious disease, inflammation, and oncology.

Officers: Michael T. Flavin, Ph.D. (Chair & CEO); John L. Flavin (Pres. & Dir.); Suseelan Pookote, Ph.D. (EVP); R. Richard Wieland II (EVP & CFO); Ze-Qi Xu Ph.D. (EVP & Chief Scientific Officer); David A. Eiznhamer, Ph.D. (EVP); Rosalie Sagraves (Dir.); Thomas V. Thornton (Dir.); Terry W. Osborn, Ph.D. (Dir.); Israel Rubinstein, M.D. (Dir.); Richard Reck (Dir.); Scott F. Meadow (Dir.); Theron E. Odlaug, Ph.D. (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock-Symbol ALDS; NasdaqGM;
28,287,677 common shares outstanding as of March 16, 2007.

Return to top

Prospector Profile 07.0504

Advancis Pharmaceutical Corporation

20425 Seneca Meadows Parkway
Germantown, MD 20876
(301) 944-6600

NAICS		541710
Employees		76
Revenue	(mil)	$4.81
Income	(mil)	($41.99)
Assets	(mil)	$42.01
Liability	(mil)	$30.13

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PricewaterhouseCoopers LLP raised substantial doubt about Advancis Pharmaceutical Corporation's ability to continue as a going concern after auditing the Company's financial statements for the years ended Dec. 31, 2006, and 2005. PwC pointed to the Company's recurring losses from operations and insufficient liquidity to fund its ongoing operations.

Intellectual Property: The Company's success depends in part on the ability to obtain patents, to protect trade secrets, to operate without infringing upon the proprietary rights of others and to prevent others from infringing on proprietary rights. The Company seeks to protect proprietary position by, among other methods, filing U.S. and foreign patent applications related to proprietary technology, inventions and improvements that are important to the development of its business. In addition, the Company intends to use license agreements to access external products and technologies, as well as to convey its intellectual property to others. The Company currently owns 25 issued U.S. patents, 23 U.S. patent applications and 2 foreign patents. The issued patents cover certain compositions and methods using pulsatile dosing. It also owns 67 foreign-filed patent applications, which correspond to U.S. patents and applications. It also owns four PCT patent applications. [SEC Filing 10-K 03-26-07]

Description: The Company engages in the development and commercialization of anti-infective drugs for the treatment various infectious diseases.

Officers: R. Gordon Douglas, M.D. (Chair); Edward M. Rudnic, Ph.D. (Pres., CEO & Dir.); Robert C. Low (VP, CFO & Treas.); Richard W. Dugan (Dir.); James H. Cavanaugh, Ph.D. (Dir.); Harold R. Werner (Dir.); Wayne T. Hockmeyer, Ph.D. (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol AVNC; NasdaqGM;
36,399,597 common shares outstanding as of February 26, 2007.

Return to top

Prospector Profile 07.0505

American Tire Distributors, Inc.

12200 Herbert Wayne Court, Suite 150
Huntersville, NC 28078
(704) 992-2000

NAICS		441320
Employees		2,074
Revenue	(mil)	$1,282.07
Income	(mil)	$25.04
Assets	(mil)	$556.30
Liability	(mil)	$498.53

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service affirmed its 'Caa1' rating on American Tire Distributors, Inc. and revised the Company's rating outlook to stable from negative. The rating agency also renewed the Company's 'SGL-2' speculative grade liquidity rating. Moody's said that the rating acknowledges the Company's dependency on purchases from a limited number of tire manufacturers and suppliers, geographic concentration of revenues in the U.S., uncertainties associated with a strategy which will likely involve future acquisitions, and low margins associated with distribution businesses.

Intellectual Property: The Company's trademarks includes private label brand names under which it markets its products. These private label brand names are important to its business because they develop brand identification and foster customer loyalty. The Company's registered trademarks include AMERICAN TIRE DISTRIBUTORS®; DYNATRAC® tires; REGUL® tires; WINSTON® tires; WYNSTAR® tires; CRUISER WIRE® custom wheels; DRIFZ® custom wheels; PACER® custom wheels; ICW® custom wheels; MAGNUM® automotive lifts; HEAFNET®; and WHEEL WIZARD®. [SEC Filing 10-K 05-01-06]

Description: The Company wholesales automobile tires that include the flagship brands of industry leaders Bridgestone, Continental, Goodyear, and Michelin, as well as budget brands and private-label tires.

Officers: Richard P. Johnson (Chair, CEO & Dir.); William E. Berry (Pres. & COO); J. Michael Gaither (EVP, Sec. & Gen. Counsel); Scott A. Deininger (SVP & Treas.); Daniel K. Brown (SVP); Phillip E. Marrett (SVP); Joseph P. Donlan (Dir.); Kim G. Davis (Dir.); Tim R. Palmer (Dir.); Jon M. Biotti (Dir.); Todd Krasnow (Dir.); M. Lenny Pippin (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: 5,161,917 common shares outstanding as of March 1, 2005.

Return to top

Prospector Profile 07.0506

Amkor Technology, Inc.

1900 South Price Road
Chandler, AZ 85248
(480) 821-5000

NAICS		333295
Employees		22,700
Revenue	(mil)	$2,728.56
Income	(mil)	$170.08
Assets	(mil)	$3,041.26
Liability	(mil)	$2,642.74

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service affirmed its 'Caa1' ratings on Amkor Technology, Inc.'s $22 million 10.5% senior subordinated notes due 2009 and $190 million 2.5% convertible senior subordinated notes due 2011. The ratings outlook is stable.

Intellectual Property: The Company has filed and obtained a number of patents in the U.S. and abroad, the duration of which varies depending on the jurisdiction in which the patent is filed. While the patents are an important element of intellectual property strategy and its success, as a whole, they are not materially dependent on any one patent or any one technology. The Company expects to continue to file patent applications when appropriate to protect proprietary technologies. It also protects certain processes, products and strategies as trade secrets, keeping confidential the information that provides a competitive advantage. To distinguish its products from competitors' products, the Company has obtained certain trademarks and service marks. [SEC Filing 10-K 02-26-07]

Description: The Company provides semiconductor assembly and test services in the U.S. It offers packaging solutions, including leadframe and laminate packages using wirebond and flip chip formats.

Officers: James J. Kim (Chair & CEO); Oleg Khaykin (EVP & COO); Kenneth T. Joyce (EVP & CFO); Roger A. Carolin (Dir.); Winston J. Churchill (Dir.); Gregory K. Hinckley (Dir.); John T. Kim (Dir.); Constantine N. Papadakis (Dir.); James W. Zug (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol AMKR; NasdaqGS;
178,109,034 common shares outstanding as of January 31, 2007.
9.25% senior notes due February 2008; 7.125% senior notes due March 2011; 7.75% senior notes due May 2013; 9.25% senior notes due June 2016; 10.5% senior subordinated notes due May 2009; 2.5% convertible senior subordinated notes due May 2011; 6.25% convertible subordinated notes due December 2013.

Return to top

Prospector Profile 07.0507

Apogee Technology, Inc.

129 Morgan Drive
Norwood, MA 02062
(781) 551-9450

NAICS		339100
Employees		12
Revenue	(mil)	$1.88
Income	(mil)	($2.97)
Assets	(mil)	$3.57
Liability	(mil)	$0.71

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Miller Wachman LLP raised substantial doubt about Apogee Technology Inc.'s ability to continue as a going concern after auditing the company's financial statements for the years ended Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's recurring operating losses and negative cash flows from operations. For the year ended Dec. 31, 2006, and 2005, the Company incurred a net loss of $3 million. Its balance sheet as of Dec. 31, 2006, showed an accumulated deficit of $15.7 million, as compared with an accumulated deficit of $12.7 million as of Dec. 31, 2005.

Intellectual Property: The Company protects the technology important to the success of its business by filing U.S. patent applications and corresponding foreign patent applications. It has filed six patent applications related to drug delivery products and has licensed exclusive rights from a third party to three additional patents. In May 2004, the Company acquired a portfolio of MEMS intellectual property, trade secrets and know-how developed by Standard MEMS, Inc, which has certain rights and royalty obligations associated with it. The Company is evaluating this intellectual property to determine what intellectual property should be utilized and filed to support its current business operations. [SEC Filing 10-K 03-29-07]

Description: The Company engages in the design, development, and marketing of sensor and medical devices based upon its micro-electromechanical systems (MEMS) and Nanotechnologies.

Officers: Herbert M. Stein (Chair); Herbert M. Stein (Pres. & CEO); Paul J. Murphy (VP & CFO); David B. Meyers (COO); Craig A. Dubitsky (Dir.); Arthur S. Reynolds (Dir.); Sheryl B. Stein (Dir.); Alan W. Tuck (Dir.)

Auditor: Miller Wachman LLP

Securities: Common Stock-Symbol ATA; AMEX;
11,968,331 common shares outstanding as of March 15, 2007.

Return to top

Prospector Profile 07.0508

Aradigm Corporation

3929 Point Eden Way
Hayward, CA 94545
(510) 265-9000

NAICS		334510
Employees		54
Revenue	(mil)	$4.81
Income	(mil)	($13.03)
Assets	(mil)	$32.23
Liability	(mil)	$36.17

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Aradigm Corp.'s balance sheet at Dec. 31, 2006, showed $32.2 million in total assets, $12.5 million in total liabilities, and $23.6 million in convertible preferred stock, resulting in a $3.9 million total stockholders' deficit. The Company reported a net loss for the fourth quarter ended Dec. 31, 2006, of $5.4 million, compared with a net loss of $10.7 million for the same period in 2005. The net loss for the year ended Dec. 31, 2006, was $13 million, compared with a net loss of $29.2 million for the same period in 2005.

Intellectual Property: As of February 28, 2007, the Company has 71 issued U.S. patents, with 20 additional U.S. patent applications pending. In addition, it has 72 issued foreign patents and additional 71 foreign patent applications pending. The bulk of patents and patent applications contain claims directed toward proprietary delivery technologies, including methods for aerosol generation, devices used to generate aerosols, breath control, compliance monitoring, certain pharmaceutical formulations, design of dosage forms and their manufacturing and testing methods. In addition, it has purchased three U.S. patents containing claims that are relevant to its inhalation technologies. The bulk of patents, including fundamental patents directed toward proprietary AERx delivery technology, expire between 2013 and 2023. The Company has in-licensed some technology and will seek to supplement such intellectual property rights with complementary proprietary processes, methods and formulation technologies, including through patent applications and trade secret protection. [SEC Filing 10-K 03-30-07]

Description: The Company is a developer of drug delivery systems that enable patients to self-administer liquid drugs that would otherwise be given by injection.

Officers: Virgil D. Thompson (Chair); Igor Gonda (Pres., CEO & Dir.); Thomas C. Chesterman (SVP & CFO); Babatunde A. Otulana (SVP & Chief Medical Officer); John J. Turanin (VP); Frank H. Barker (Dir.); Stephen O. Jaeger (Dir.); John M. Siebert (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol ARDM.OB; OTC BB;
53,946,300 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0509

BIO-key International Inc.

3349 Highway 138, Building D, Suite B
Wall, NJ 07719
(732) 359-1100

NAICS	334119	
Employees	100	
Revenue	(mil)	$15.19
Income	(mil)	($11.08)
Assets	(mil)	$20.46
Liability	(mil)	$17.15

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Carlin, Charron, & Rosen LLP raised substantial doubt on BIO-Key International, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the year ended Dec. 31, 2006. The auditing firm pointed to the Company's substantial net losses in recent years and an accumulated deficit at Dec. 31, 2006. The Company reported a net loss of $11.1 million on total revenues of $15.2 million for the year 2006, versus a net loss of $3.7 million on total revenues of $14.2 million for the prior year.

Intellectual Property: In May 2005, the U.S. Patent & Trademark Office issued a patent for its Vector Segment fingerprint technology, BIO-key's core biometric analysis and identification technology. On August 29 2006, the Company's patent for biometric identification indexing was granted in Europe. In addition, a WEB-key® authentication security patent for "Systems and Methods of Secure Biometric Authentication" has been issued in South Africa. On October 3, 2006, BIO-key announced that a patent for a biometric authentication security framework has been granted by the U.S. Patent & Trademark Office. On January 11, 2007, BIO-key was issued US patent No. 7,155,040 covering its unique image processing technology, which is critical for enhancing information used in the extraction of biometric minutiae. The Company has registered its trademarks, including "BIO-key", "True User Identification", "WEB-key", "PacketCluster", "PacketCluster Patrol", "PacketWriter", "PocketCop", "VirtualCop", "MobileCop", and the design mark for "Ceurulean", with the U.S. Patent & Trademark Office. It has also applied for trademarks for "Cerulean". [SEC Filing 10-K 03-29-07]

Description: The Company develops and markets fingerprint identification biometric technology and software solutions, and information services in the United States.

Officers: Thomas J. Colatosti (Chair); Michael W. DePasquale (CEO & Dir.); Francis J. Cusick (CFO); Randy Fodero (VP-Sales); Kenneth S. Souza (Chief Technology Officer); Jeffrey J. May (Dir.); Charles P. Romeo (Dir.); John Schoenherr (Dir.)

Auditor: Carlin, Charron, & Rosen LLP

Securities: Common Stock-Symbol BKYI.OB; OTC BB;
56,591,104 common shares outstanding as of March 1, 2007.

Return to top

Prospector Profile 07.0510

Biosolar, Inc.
27936 Lost Canyon Road, Suite 202
Santa Clarita, CA 91387
(661) 251-0001

NAICS		541710
Employees		1
Revenue	(mil)	$0.00
Income	(mil)	($0.27)
Assets	(mil)	$1.22
Liability	(mil)	$0.04

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: HJ Associates & Consultants, LLP expressed doubt on the ability of Biosolar, Inc. to continue as a going concern. The Company is dependent on the ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to achieve profitable operations.

Intellectual Property: On June 27, 2006, the Company filed a patent to protect the intellectual property rights for "A Method for Building Thin Film Flexible Solar Cells on Bio-Based Plastic Substrates", application number 11/476,518. The inventor listed on the patent application is CEO David Lee, and the Company is listed as the assignee. The Company also relies upon confidentiality agreements signed by employees, consultants and third parties to protect intellectual property. [SEC Filing 10-KSB 03-19-07]

Description: The Company is developing new and innovative thin film solar cells produced on bio-based plastic substrates with the intent to provide commercially viable solar cell designs that convert sun light into electrical energy.

Officers: David Lee (CEO & Acting CFO); Steven C. Bartling (Dir.); Dennis LePon (Dir.)

Auditor: HJ Associates & Consultants, LLP

Securities: Common Stock-Symbol BSRC.OB; OTC BB;
128,557,777 common shares outstanding as of March 14, 2007.

Return to top

Prospector Profile 07.0511

Ceragenix Pharmaceuticals, Inc.

1444 Wazee Street, Suite 210
Denver, CO 80202
(720) 946-6440

NAICS		541710
Employees		5
Revenue	(mil)	$0.00
Income	(mil)	($4.55)
Assets	(mil)	$6.33
Liability	(mil)	$8.39

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: GHP Horwath, P.C. raised doubts on Ceragenix Pharmaceuticals, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has not generated revenue or cash flow from operations since inception, has incurred continuing losses and has a stockholders' deficit at December 31, 2006. While management believes that existing cash will be sufficient to fund corporate activities, current contractual obligations and minimal development activities in 2007, this assumes that the $2,950,000 in convertible notes which mature in 2007 will be converted to shares of common stock. However, there is no assurance that these shares will be converted at maturity.

Intellectual Property: The Company has an exclusive license agreement with the Regents of the University of California for Barrier Repair technology dated June 28, 2000. The license agreement provides for the exclusive rights to commercially develop, use and sell therapeutic and cosmetic applications for the Barrier Repair technology. It also has an exclusive license agreement with Brigham Young University for the intellectual property rights to Ceragenin™ technology dated May 1, 2004. To date, the Company has conducted research related to the Ceragenin™ technology for use as an antibiotic, antiviral agent, anticancer agent and antifungal agent. The US Patent and Trademark Office has approved these trademark registrations: EpiCeram™, NeoCeram™, Ceracide™, Ceragenins™ and Ceragenix™. It also has a pending trademark application on file for Cerashield™. [SEC Filing 10-KSB 03-19-07]

Description: The Company engages in the discovery, development, and commercialization of a portfolio of products for dermatology, oncology, and infectious disease applications.

Officers: Steven S. Porter (Chair, CEO & Dir.); Jeffrey Sperber (CFO & Dir.); Dr. Peter Elias (Chief Scientific Officer); Carl Genberg (SVP); Russell L. Allen (VP)

Auditor: GHP Horwath, P.C.

Securities: Common Stock-Symbol CGXP.OB; OTC BB;
16,174,991 common shares outstanding as of March 16, 2007.

Return to top

Prospector Profile 07.0512

Ciphergen Biosystems, Inc.
6611 Dumbarton Circle
Fremont, CA 94555
(510) 505-2100

NAICS		541710
Employees		36
Revenue	(mil)	$18.22
Income	(mil)	($22.07)
Assets	(mil)	$23.02
Liability	(mil)	$32.92

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PricewaterhouseCoopers LLP expressed doubt on Ciphergen Biosystems, Inc.'s ability to continue as a going concern due to its recurring losses, negative cash flows from operations and net capital deficiency. The Company reported net losses of $22 million and $35.4 million for the years ended Dec. 31, 2006, and 2005, respectively. As of Dec. 31, 2006, the Company posted total assets amounting to $23 million and total liabilities amounting to $32.9 million, resulting to total stockholders' deficit of $9.9 million.

Intellectual Property: As of December 31, 2006, the Company's patent portfolio included 9 issued U.S. patents, 54 pending U.S. patent applications and numerous pending patent applications and issued patents outside the U.S. These patents and patent applications are directed to several areas of technology important to its business, including the core SELDI technology, diagnostic applications, protein biochips, instrumentation, software and biomarkers. The Company entered into a cross license agreement with Bio-Rad pursuant to which it retained the right to commercially exploit proprietary rights, including SELDI technology, in the clinical diagnostics market. The rights to the core SELDI technology are derived through royalty-bearing sublicenses from Molecular Analytical Systems, Inc., which holds an exclusive license to patents directed to the SELDI technology from the owner, Baylor College of Medicine. As of December 31, 2006, 46 of its patent applications are directed to biomarker inventions and 8 are dedicated to diagnostic applications. [SEC Filing 10-K 04-02-07]

Description: The Company engages in the development, manufacture, and marketing of proteomics research equipment.

Officers: James L. Rathmann (Chair); Gail S. Page (Pres., CEO & Dir.); Debra A. Young (SVP & CFO); John A. Young (Dir.); Judy Bruner (Dir.); James S. Burns (Dir.); Michael J. Callaghan (Dir.); Kenneth J. Conway (Dir.); Rajen K. Dalal, Ph.D. (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol CIPH; NasdaqCM;
39,240,749 common shares outstanding as of March 26, 2007.

Return to top

Prospector Profile 07.0513

Concierge Technologies, Inc.
22048 Sherman Way, Suite 301
Canoga Park, CA 91303
(818) 610-0310

NAICS 517212

Revenue	(mil)	$0.04
Income	(mil)	($0.04)
Assets	(mil)	$0.00
Liability	(mil)	$0.53

(for the year ended 6/30/2006)

Category: Audit Concerns

Event: Kabani & Company Inc. expressed substantial doubt on Concierge Technologies, Inc.'s ability to continue as a going concern. The Company has not earned any revenue since its inception and has accumulated deficit of $3,909,313 at June 30, 2006, including a net loss of $44,552 during the year ended June 30, 2006.

Intellectual Property: Concierge has trademarked its Personal Communications Attendant but has no patents on the product. The Company's Planet Halo subsidiary has trademarked the names "Halo", "Halomail", and "Planet Halo". Patent applications are pending on certain aspects of the Halo device and software applications that enable certain of its functionality. Know-how centered around the programming, low-level drivers, key board matrix, operating system interface and certain other aspects of the Halo device, including its industrial design, are considered a valued intellectual property of Planet Halo. [SEC Filing 10-KSB/A 03-20-07]

Description: The Company and its subsidiaries operate in the wireless telecommunications industry. The Company engages in developing and marketing Personal Communications Attendant, a unified messaging product that enables users of Internet email to retrieve email messages from any touch-tone telephone or wireless phone.

Officers: Allen E. Kahn (Chair, CEO & CFO); David W. Neibert (Pres. & Dir.); James E. Kirk (Sec. & Dir.); Samuel Wu (Dir.); Patrick Flaherty (Dir.); Marc Angell (Dir.); Pat Rodden (Dir.)

Auditor: Kabani & Company Inc.

Securities: Common Stock-Symbol CNCG.OB; OTC BB;
147,292,747 common shares outstanding as of February 8, 2007.

Return to top

Prospector Profile 07.0514

Covalence Specialty Materials Corp.

1 Crossroads Drive, Building A
Bedminster, NJ 07921
(908) 547-6061

NAICS		326100
Employees		7,125
Revenue	(mil)	$366.70
Income	(mil)	($21.80)
Assets	(mil)	$1,089.80
Liability	(mil)	$941.00

(for the year ended 12/29/2006)

Category: Low Rating

Event: Moody's Investors Service downgraded the rating of Covalence Specialty Materials Corp.'s $265 million senior subordinated notes due 2016 to Caa1, LGD6, 90%. The rating outlook is stable. Moody's said the notes became obligations of Berry Plastics Holding Corp. upon the closing of its stock-for-stock merger with the Company on March 13, 2007. The difference in product lines and size of the Company represents a material change to Berry's operating profile and source of integration risk. Required investments for synergies will leave no free cash flow for debt reduction in the near term and little cushion for any negative variance.

Intellectual Property: The Company holds more than 250 issued and pending patents relating to the design, use and manufacture of products, and it regularly applies for new patents on significant product and process developments. The Company has registered trademarks on substantially all of its brand names, and believes that it has adequately protected trademark position in all markets in which it does business. [SEC Filing S-4 09-27-06]

Description: Covalence Specialty Materials Corp. manufactures plastic sheeting, shrink wrap, coatings, laminates, house wrap, and stretch film. The Company completed its stock-for-stock merger with Berry Plastics Holding Corp. on April 3, 2007 and the combined companies will known as Berry Plastics Group, Inc.

Officers: Marvin O. Schlanger (Chair); Layle K. Smith (Pres. & CEO); David S. Graziosi (EVP & CFO); Peter B. Blackadar (VP & Controller); Gail E. Lehman (VP, Gen. Counsel, & Sec.); Gary J. Powell (VP-Operations)

Securities: 10.25% senior subordinated notes due March 1, 2016

Return to top

Prospector Profile 07.0515

Diomed Holdings, Inc.

1 Dundee Park
Andover, MA 01810
(978) 475-7771

NAICS		334510
Employees		100
Revenue	(mil)	$22.38
Income	(mil)	($10.27)
Assets	(mil)	$23.84
Liability	(mil)	$28.02

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Diomed Holdings, Inc. reported a net loss of $10,269,01 for the year ended December 31, 2006 on sales of $22,382,311, lower than the net loss reported last year of $11,437,637 on sales of $19,048,751. As a result of its recurring losses, the Company has an accumulated deficit of $91,118,735 at December 31, 2006.

Intellectual Property: The Company holds U.S. and international patents for inventions related to endovenous laser treatment of varicose veins, solid state laser diode light source, high power light source, peltier-cooled and medical spacing guide. The Company licensed technology for the EVLT® process from one of its inventors, Dr. Robert Min. On September 3, 2003, Diomed acquired exclusive rights to U.S. and foreign patents for endovenous laser treatment of varicose veins. The Company also invented fiber technology used with its EVLT® products. In January 2006, the U.S. Patent and Trademark Office issued two additional patents used in connection with EVLT®, for the introducer sheath/optical fiber arrangement that may be used in the endovascular laser treatment of varicose veins. The Company licenses technology used in its OPTIGUIDE® fiber optic diffuser from Health Research, Inc. The Company has received trademark registrations for the trademarks "Diomed," "OPTIGUIDE" and "EVLT" and has initiated trademark registrations for "Summer Legs," "Spotlight" and "Spotlight OPS." The Company has registered various domain names, including diomedinc.com, diomed-lasers.com, fibersdirect.com, fibresdirect.com, summerlegs.com and evlt.com. [SEC Filing 10-K 03-19-07]

Description: The Company, through its subsidiaries, engages in the development and commercialization of minimally invasive medical procedures that employ its laser technologies.

Officers: James A. Wylie, Jr. (Pres., CEO & Dir.); David Swank (CFO & Dir.); Geoffrey Jenkins (Dir.); Sidney Braginsky (Dir.); Gary Brooks (Dir.); A. Kim Campbell (Dir.); Joseph Harris (Dir.); Peter Klein (Dir.); Edwin Snape, Ph. D. (Dir.)

Auditor: BDO Seidman LLP

Securities: Common Stock-Symbol DIO; AMEX;
23,535,728 common shares outstanding as of March 14, 2007.

Return to top

Prospector Profile 07.0516

Edgen Murray LP

18444 Highland Road
Baton Rouge, LA 70809
(225) 756-9868

NAICS		331513
Revenue	(mil)	$397.68
Income	(mil)	$11.94
Assets	(mil)	$248.49
Liability	(mil)	$206.54

(for the year ended 12/31/2006)

Category: Low Rating

Event: Standard & Poor's Ratings Services assigned a 'CCC+/RR5' rating on Edgen Murray LP's proposed $75 million second-lien term loan due 2015. The rating outlook is stable. According to Standard & Poor's credit analyst Marie Shmaruk, the Company's debt level is at a historical peak, and the Company's limited end-market focus leaves it susceptible to prolonged downturns in a highly competitive and low-margin industry. Moody's Investors Service also assigned a 'Caa1, LGD4, 65% ratings to the Company's proposed $300 million senior unsecured fixed rate notes due 2014 and $150 million senior unsecured floating rate notes due 2013.

Intellectual Property: The Company has common law trademark rights to a number of names and marks important to its business, including Edgen™, Bartow Steel™, Resource Pipe Co.™, SISCO™, Thomas Pipe™, Pro Metals™, and Radnor Alloys™, although it has not obtained federal registrations for them. The Company has also entered into licensing arrangements with several owners of intellectual property rights. [SEC Filing 10-K 03-30-07]

Description: Edgen Murray LP, a subsidiary of Edgen Murray Corp., distributes carbon steel and alloy products for use primarily in specialized applications in the energy and niche industrial segments.

Officers: Daniel J. O'Leary (CEO & Dir.); David L. Laxton III (EVP, CFO & Dir.); Robert L. Gilleland (SVP-Global Supply Chain & Vendor Dev't.)

Auditor: Deloitte & Touche LLP

Notes: The financial information provided is that of the parent company, Edgen Murray Corp.

Return to top

Prospector Profile 07.0517

Fedders Corporation

505 Martinsville Road
Liberty Corner, NJ 07938
(908) 604-8686

NAICS		238220
Employees		1,664
Revenue	(mil)	$279.26
Income	(mil)	($124.62)
Assets	(mil)	$181.36
Liability	(mil)	$302.73

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Fedders Corp. posted a net loss of $124,624,000 on revenues of $279,255,000 for the year ended December 31, 2006, compared to a net loss of $62,081,000 on revenues of $297,716,000 in 2005. As of December 31, 2006, the Company's balance sheet showed strained liquidity with $86,216,000 in total current assets and $102,145,000 in total current liabilities. The Company also reported $121,366,000 in stockholders' deficit and $205,571,000 in accumulated deficit.

Intellectual Property: The Company owns a number of trademarks, and licenses the name MAYTAG from Maytag Corporation for use on air conditioners. While the Company believes that its trademarks, such as FEDDERS, ADDISON, AIRTEMP, TRION, SUN, KOPPEL, EUBANK, and MAC-10, as well as the trademark MAYTAG, are well known and enhance the marketing of its products, the Company does not consider the successful conduct of its business to be dependent upon such trademarks. The Company aggressively protects its trademark and intellectual property rights worldwide. [SEC Filing 10-K 03-30-07]

Description: The Company produces and markets air treatment products for the residential, commercial, and industrial markets through its Heating, Ventilation, and Air Conditioning (HVAC); and Engineered Products business segments.

Officers: Salvatore Giordano, Jr. (Chair); Michael Giordano (Pres. & CEO); Kent E. Hansen (EVP-Admin., Sec., & Gen. Counsel); Robert L. Laurent, Jr. (EVP-Finance & Acquisitions, & CFO); Peter Gasiewicz (SVP); Judy A. Katz (VP-Strategic Planning & Corporate Mktg.); Nancy DiGiovanni (VP & Treas.); Jordan Bruno (VP-Taxes); Michael D. Webb (VP-Financial Analysis); Warren Emley (VP); Mark Mishler (Controller)

Auditor: UHY LLP

Securities: Common Stock Symbol FJCC.PK; Other OTC;
32,020,380 common shares outstanding as of March 1, 2007.
9-7/8% senior notes due 2014.

Return to top

Prospector Profile 07.0518

Fonix Corporation

9350 South 150 East, Suite 700
Sandy, UT 84070
(801) 553-6600

NAICS 541512

Revenue	(mil)	$1.33
Income	(mil)	($21.94)
Assets	(mil)	$2.81
Liability	(mil)	$55.95

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Hansen, Barnett & Maxwell PC raised substantial doubt about Fonix Corporation's ability to continue as a going concern after auditing the company's financial statements for the years ended Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's significant losses and negative cash flows from operating activities during each of the three years in the period ended Dec. 31, 2006.

Intellectual Property: The Company's success is heavily dependent upon proprietary technology. Certain elements of its core technologies are the subject of nine patents issued and allowed by the U.S. Patent and Trademark Office and seven other pending patent applications. In addition to patents, the Company relies on a combination of copyright and trademark laws, trade secrets, confidentiality procedures and contractual provisions to protect proprietary rights. [SEC Filing 10-K 03-29-07]

Description: The Company delivers speech interface solutions and applications that help people to interact conversationally with information systems and computing devices.

Officers: Thomas A. Murdock (Pres., CEO & Dir.); Roger D. Dudley (EVP, CFO & Dir.); William A. Maasberg, Jr. (COO & Dir.)

Auditor: Hansen, Barnett & Maxwell

Securities: Common Stock-Symbol FNIX.OB; OTC BB;
1,642,139,820 common shares outstanding as of March 19, 2007.

Return to top

Prospector Profile 07.0519

Innovive Pharmaceuticals, Inc.

555 Madison Avenue, 25th Floor
New York, NY 10022
(212) 716-1810

NAICS		541710
Employees		9
Revenue	(mil)	$0.00
Income	(mil)	($17.50)
Assets	(mil)	$4.29
Liability	(mil)	$2.83

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: J.H. Cohn LLP expressed substantial doubt about Innovive Pharmaceuticals, Inc.'s ability to continue as a going concern after auditing its financial statements. The Company has incurred net losses and negative net cash flows from operating activities from inception through December 31, 2006 and has an accumulated deficit and limited working capital as of December 31, 2006.

Intellectual Property: The Company actively seeks the broadest intellectual property protection available for its current product candidates, future product candidates and any other proprietary technologies and/or assets through a combination of strategic contractual alliances and diversified intellectual property protection and enforcement, worldwide. In December 2005, the Company entered into an exclusive worldwide royalty-bearing license agreement with Nippon Shinyaku, including the right to grant sub-licenses, for the intellectual property relating to INNO-406 in any field. On December 6, 2006, the Company entered into a license agreement with TMRC Co., Ltd. for the license of patent rights held by TMRC for the North American development and commercialization of tamibarotene. On August 18, 2006, the Company entered into a license agreement with KTB Tumorforschungs GmbH for the license of patent rights held by KTB for the worldwide development and commercialization of INNO-206. In December 2005, the Company entered into an exclusive worldwide royalty-bearing license agreement with the Sloan-Kettering Institute for Cancer Research including the right to grant sub-licenses, for the intellectual property relating to INNO-305 for all diseases, disorders and/or conditions, including but not limited to, oncology. [SEC Filing 10-K 03-21-07]

Description: The Company engages in the development of compounds for the treatment of cancer.

Officers: Steven Kelly (Pres., CEO & Dir.); Adam Craig, M.D., Ph.D. (VP & Chief Medical Officer); J. Gregory Jester (VP & CFO); Eric Poma, Ph.D. (VP & Sec.)

Auditor: J.H. Cohn LLP

Securities: Common Stock-Symbol IVPH.OB; OTC BB;
9,147,068 common shares outstanding as of March 20, 2007.

Return to top

Prospector Profile 07.0520

Integral Vision, Inc.

49113 Wixom Tech Drive
Wixom, MI 48393
(248) 471-2660

NAICS		334119
Employees		18
Revenue	(mil)	$0.84
Income	(mil)	($2.97)
Assets	(mil)	$0.88
Liability	(mil)	$1.30

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Rehmann Robson raised substantial doubt about Integral Vision, Inc.'s ability to continue as a going concern due to its recurring losses from operations and difficulties in achieving the necessary sales to attain profitability.

Intellectual Property: The technology incorporated in the Company's products gives advantages over its competitors and prospective competitors. Protection of technology is attempted through a combination of patents, applied for patents, confidentiality agreements and trade secrets. The Company presently has 14 U.S. patents. [SEC Filing 10-KSB 03-19-07]

Description: The Company engages in the development, manufacture, and marketing of flat panel display inspection systems for display manufacturing process.

Officers: Charles J. Drake (Chair & CEO); Max A. Coon (Vice Chair & Sec.); Mark R. Doede (Pres., COO & CFO); Andrew Blowers (CTO); Arthur D. Harmala (VP-Mktg.); Mark A. Michniewicz (VP - Eng'g.); Vincent Shunsky (Dir.); William B. Wallace (Dir.); Samuel O. Mallory (Dir.)

Auditor: Rehmann Robson

Securities: Common Stock-Symbol INVI.OB; OTC BB;
29,511,409 common shares outstanding as of March 17, 2007.

Return to top

Prospector Profile 07.0521

iPCS, Inc.

1901 North Roselle Road
Schaumburg, IL 60195
(847) 885-2833

NAICS		517212
Employees		500
Revenue	(mil)	$492.42
Income	(mil)	($46.04)
Assets	(mil)	$627.07
Liability	(mil)	$412.89

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service assigned a Caa1, LGD5, 75% rating on iPCS, Inc.'s $175 million second lien senior secured floating rate notes due 2014. The rating agency changed the rating outlook to developing. Moody's said that Company's outlook change is based on their concerns on the Company's financial and operating implications associated with the ongoing disputes and lawsuits that the Company is currently engaged with its parent, Sprint Nextel Corp.

Intellectual Property: The Company has a non-transferable license to use the Sprint and Sprint PCS brand names and several other U.S. trademarks and service marks on Sprint PCS products and services. The Company believes that the Sprint and Sprint PCS brand names and symbols enjoy a high degree of recognition, providing an immediate benefit in the marketplace. [SEC Filing 10-K 03-16-07]

Description: The Company provides wireless voice and data products and services and sells digital wireless personal communications services in the U.S.

Officers: Timothy M .Yager (Pres. & CEO); Stebbins B. Chandor, Jr. (EVP & CFO); John J. Peterman (SVP-Sales); Patricia M. Greteman (VP & Controller); Edmund L. Quatmann, Jr. (VP, Gen. Counsel, & Sec.); Timothy G. Biltz (Dir.); Jeffrey W. Jones (Dir.); Ryan L. Langdon (Dir.); Richard S. Parisi (Dir.); Kevin M. Roe (Dir.); Eric L. Zinterhofer (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock Symbol IPCX.OB; OTCBB;
16,934,585 common shares outstanding as of March 7, 2007.
11-1/2% senior notes due 2012; 11-3/8% senior notes due 2012; 14% senior discount notes due July 15, 2010.

Return to top

Prospector Profile 07.0522

Magstar Technologies, Inc.

410 11th Avenue South
Hopkins, MN 55343
(952) 935-6921

NAICS		326220
Employees		59
Revenue	(mil)	$9.98
Income	(mil)	$0.81
Assets	(mil)	$2.19
Liability	(mil)	$4.75

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Virchow, Krause & Company LLP raised substantial doubt about MagStar Technologies, Inc.'s ability to continue as a going concern after auditing the company's financial statements as of Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's recurring losses from operations and total liabilities exceeding total assets. The Company's balance sheet as of Dec. 31, 2006 reflected total stockholders' deficit of $2.5 million and accumulated deficit of $28.1million. The Company also had working capital of $586,603, as compared with a working capital deficit of $3 million at Dec. 31, 2005.

Intellectual Property: The Company has four patents on its Quickdraw Conveyor products and trademarks on its oil centrifuge product and conveyor products. The Company also has its employees sign confidentiality and nondisclosure agreements at the time of hiring. [SEC Filing 10-KSB 03-29-07]

Description: The Company is a leading global provider of products, technologies, solutions, and services to businesses of all sizes.

Officers: Richard F. McNamara (Chair); Jon L. Reissner (Pres., CEO, Sec. & Dir.); Joseph A. Petrich (CFO & Treas.); Duane R. Bryngelson (COO); David E. Helgerson (CTO); James L. Reissner (Dir.); Michael J. Tate (Dir.); Robert L. Stehlik (Dir.); Dr. James H. Zavoral (Dir.)

Auditor: Virchow, Krause & Company, LLP

Securities: Common Stock-Symbol MGST.OB; OTC BB;
9,137,223 common shares outstanding as of March 19, 2007.

Return to top

Prospector Profile 07.0523

MDwerks, Inc.

Windolph Center, 1020 NW 6th Street
Deerfield Beach, FL 33442
(954) 389-8300

NAICS		524291
Employees		18
Revenue	(mil)	$0.43
Income	(mil)	($9.68)
Assets	(mil)	$4.41
Liability	(mil)	$2.10

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Goldstein Golub Kessler LLP raised doubt on MDwerks, Inc.'s ability to continue as a going concern due to its recurring losses from operations.

Intellectual Property: A U.S. business process patent application regarding certain aspects of its system was filed by its predecessor, MEDwerks, LLC, on April 15, 2002. The U.S. Patent Office has issued an initial office action indicating that it will not allow a patent based upon the initial application. The Company's patent counsel, DLA Piper Rudnick Gray Cary has modified patent application based upon the U.S. Patent Office's action and has submitted a response to the office action. The Company plans to undertake prosecution of the patent filing to conclusion, if practical and economical. [SEC Filing 10-KSB 03-21-07]

Description: The Company, through its wholly owned subsidiaries, offers medical insurance claims processing, management, and financing solutions for healthcare providers.

Officers: Solon Kandel (Pres. & Dir.); Howard Katz (CEO & Dir.); Vincent Colangelo (Sec. & CFO); Lila Sobel (COO); Stephen M. Weiss (CTO); Gerard Maresca (VP-Bus. Dev't.); David M. Barnes (Dir.); Peter Dunne (Dir.); Paul Kushner (Dir.)

Auditor: Goldstein Golub Kessler LLP

Securities: Common Stock-Symbol MDWK.OB; OTC BB;
12,580,065 common shares outstanding as of March 16, 2007.

Return to top

Prospector Profile 07.0524

MicroMed Cardiovascular, Inc.

8965 Interchange Drive
Houston, TX 77054
(713) 838-9210

NAICS		334510
Employees		34
Revenue	(mil)	$3.05
Income	(mil)	($8.23)
Assets	(mil)	$13.89
Liability	(mil)	$2.07

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: MicroMed Cardiovascular, Inc. reported a net loss of $8,228,798 on revenues of $3,049,410 for the year ended December 31, 2006, lower than the net loss reported last year of $8,945,857 on revenues of $5,158,178. As a result of its recurring losses, the Company reported an accumulated deficit of $93,595,720 as of December 31, 2006.

Intellectual Property: The pump technology used in the DeBakey VAD is protected by a patent issued to NASA in 1996. The Company signed a patent license agreement with NASA to be the exclusive licensee to this technology for use in cardiovascular applications. Separate agreements with Baylor College of Medicine and NASA gives the Company the exclusive right to the continuation of the VAD technology modifications. The Company also made foreign patent application filings covering the technology in December 1996, which has been issued in certain foreign jurisdictions. It has also obtained an additional patent covering unique features of an external controller and data acquisition system, and a patent for a proprietary pulsatile loop system. The Company has filed five patent applications related to suction detection and physiologic algorithms. In addition, it has received a registered trademark for the use of the name "DeBakey VAD". [SEC Filing 10-KSB 03-19-07]

Description: The Company develops a miniaturized heart pump known as the DeBakey VAD to address congestive heart failure.

Officers: Clifford zur Nieden (Int. CEO & Dir.); Robert J. Benkowski (COO); Juliet Markovich (SVP & CFO); Alan D. Totah (SVP)

Auditor: Singer Lewak Greenbaum & Goldstein LLP

Securities: Common Stock-Symbol MMCV.OB; OTC BB;
39,915,402 common shares outstanding as of March 14, 2007.

Return to top

Prospector Profile 07.0525

NeoMedia Technologies, Inc.
2201 Second St., Suite 600
Fort Myers, FL 33901
(239) 337-3434

NAICS		541512
Employees		134
Revenue	(mil)	$10.31
Income	(mil)	($67.44)
Assets	(mil)	$38.13
Liability	(mil)	$92.66

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Stonefield Josephson, Inc. raised substantial doubt about NeoMedia Technologies Inc.'s ability to continue as a going concern after auditing the company's financial statements as of Dec. 31, 2006, and 2005. Stonefield Josephson pointed to the Company's significant operating losses, negative cash flows from operations and working capital deficit. The Company reported a net loss of $67.4 million on net sales of $10.3 million for the year ended Dec. 31, 2006. As of Dec. 31, 2006, the Company's balance sheet showed a shareholders' deficit of $54.5 million and accumulated deficit of $160 million.

Intellectual Property: NeoMedia's success in the physical-world-to-Internet market is dependent upon its proprietary technology, including patents and other intellectual property, and on the ability to protect proprietary technology and other intellectual property rights. NeoMedia also intends to rely upon unpatented trade secrets and the know-how and expertise of its employees. To protect its proprietary technology and other intellectual property, NeoMedia relies primarily on a combination of the protections provided by applicable patent, copyright, trademark, and trade secret laws as well as on confidentiality procedures and licensing arrangements. NeoMedia licenses from third parties certain software tools that are included in its services and products. If any of these licenses were terminated, NeoMedia could be required to seek licenses for similar software from other third parties or develop these tools internally. [SEC Filing 10-K 04-03-07]

Description: The Company develops proprietary technologies that link physical information and objects to the Internet.

Officers: Charles W. Fritz (Chair); Charles T. Jensen (Pres., CEO & Dir.); David A. Dodge (VP & CFO); Martin N. Copus (COO); William E. Fritz (Dir.); James J. Keil (Dir.); A. Hayes Barclay (Dir.)

Auditor: Stonefield Josephson, Inc.

Securities: Common Stock-Symbol NEOM.OB; OTC BB;
897,194,732 common shares outstanding as of March 19, 2007.

Return to top

Prospector Profile 07.0526

New World Restaurant Group, Inc.

1687 Cole Blvd.
Golden, CO 80401
(303) 568-8000

NAICS 311812

Revenue	(mil)	$389.96
Income	(mil)	($6.87)
Assets	(mil)	$133.15
Liability	(mil)	$265.39

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: New World Restaurant Group, Inc. reported a net loss in fiscal year 2006 of $6.9 million, a 51% improvement over the net loss of $14 million in 2005. At Jan. 2, 2007, the Company's balance sheet showed $133.2 million in total assets and $265.4 million in total liabilities, resulting in a $132.2 million total stockholders' deficit. The Company's balance sheet at Jan. 2, 2007, also showed strained liquidity with $24.9 million in total assets available to pay $32.9 million in total current liabilities.

Intellectual Property: The Company's rights in trademarks and service marks are a significant part of its business. The Company owns the federal registration rights to the "Einstein Bros.," "Noah's New York Bagels" and "Manhattan Bagel" marks, as well as several related word marks and design marks related to its core brands. The Company licenses the rights to use certain trademarks to franchisees and licensees in connection with their operations. Many of its core brand trademarks are also registered in numerous foreign countries. [SEC Filing 10-K 03-07-07]

Description: The Company is an operator of bagel bakeries in the United States. The Company operates and licenses locations primarily under the Einstein Bros. and Noah's New York Bagels brand names and franchises locations primarily under the Manhattan Bagel and Chesapeake Bagel Bakery brand names.

Officers: Paul J.B. Murphy, III (Pres., CEO & Dir.); Jill B.W. Sisson (Gen. Counsel & Sec.); Daniel J. Dominguez (COO); Richard P. Dutkiewicz (CFO); Michael W. Arthur (Dir.); E. Nelson Heumann (Dir.); James W. Hood (Dir.); Frank C. Meyer (Dir.); S. Garrett Stonehouse, Jr. (Dir.); Leonard Tannenbaum (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock-Symbol NWRG.PK; PNK;
10,593,085 common shares outstanding as of November 8, 2006.

Return to top

Prospector Profile 07.0527

Phoenix Footwear Group, Inc.

5840 El Camino Real, Suite 106
Carlsbad, CA 92008
(760) 602-9688

NAICS		316210
Employees		543
Revenue	(mil)	$140.59
Income	(mil)	($20.38)
Assets	(mil)	$107.43
Liability	(mil)	$75.59

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Grant Thornton LLP raised substantial doubt about the ability of Phoenix Footwear Group, Inc. to continue as a going concern after auditing the Company's financial statements for the years ended December 31, 2006, and 2005. The auditing firm pointed to the Company's net losses, working capital deficit, and negative cash flows.

Intellectual Property: The Company regards proprietary rights as valuable assets and as important to its competitive advantage. The Company's trademarks include Trotters, SoftWalk, H.S. Trask, Royal Robbins, Chambers Belts and Altama, which are registered in the U.S. and many foreign countries. Its SoftWalk brand contains a patented technology in the foot bed of the shoe, for which it owns a patent in the U.S. The Company also holds licenses to design and distribute products bearing trademarks owned by other entities. It has an exclusive license from Tommy Bahama Group, Inc. to design and distribute men's and women's footwear, hosiery, belts and men's small leather goods and accessories bearing the "Tommy Bahama®" mark and related marks used in the Premium Footwear business. The Company also holds exclusive licenses from Wrangler Apparel Corp. to distribute leather belts, accessories, and suspenders bearing the "Wrangler®" mark and related marks for its accessories segment. These licenses are very important to sales in these segments. [SEC Filing 10-K 04-05-07]

Description: The Company designs, develops, and markets men's and women's footwear, belts, and outdoor apparel in the U.S.

Officers: James R. Reidman (Chair & CEO); Kenneth E. Wolf (CFO, Sec. & Treas.); Steven M. DePerrior (Dir.); Robert A. Gunst (Dir.); Gregory M. Harden (Dir.); John C. Kratzer (Dir.); Wilhelm Pfander (Dir.); Frederick R. Port (Dir.); John M. Robbins (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock Symbol PXG; AMEX;
8,382,762 common shares outstanding as of March 27, 2007.

Return to top

Prospector Profile 07.0528

Pregis Corporation

1900 West Field Court
Lake Forest, IL 60045
(847) 482-2259

NAICS 326112

Revenue	(mil)	$925.50
Income	(mil)	($8.40)
Assets	(mil)	$797.03
Liability	(mil)	$652.77

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service affirmed its Caa1, LGD5, 83% rating on Pregis Corp.'s $150 million senior subordinated notes due 2013. The rating outlook is changed to negative from stable. Moody's said that the negative outlook reflects its belief that the Company's operating performance will continue to fall short of the expectations that the rating agency set when it initially rated the Company in September 2005.

Intellectual Property: The Company has selectively pursued protection afforded by patents and trademarks whenever deemed critical. It also relies upon unregistered trademarks and copyrights, proprietary know-how and trade secrets. The major trademarks of its Global Protective Packaging division include Astro-Foam™, Astro-Cell®, Astro-Bubble®, Air Kraft®, Furniture GUARD®, Hexacomb®, Jiffy™, Microfoam®, Nopaplank™, Polylam™ and Polyplank®. The major trademarks of European Specialty Packaging include Propyflex™, Secu-Drape™, Cleerpeel™, Steriflex™, Mediwell Super™, Mediwell Super Plus™, Medipeel™ and Flexopeel™. [SEC Filing S-4 12-15-05]

Description: The Company manufactures, markets and supplies protective packaging products and specialty packaging solutions.

Officers: Michael T. McDonnell (Pres., CEO, & Dir.); Timothy J. Cunningham (CFO); Steven Huston (VP, Gen. Counsel, & Sec.)

Auditor: Ernst & Young LLP

Notes: The financial information is that of Pregis Holding II Corp.'s Form 10-K that was not filed with the U.S. Securities and Exchange Commission.

Return to top

Prospector Profile 07.0529

Provectus Pharmaceuticals, Inc.

7327 Oak Ridge Highway, Suite A
Knoxville, TN 37931
(865) 769-4011

NAICS		541710
Employees		4
Revenue	(mil)	$0.00
Income	(mil)	($8.87)
Assets	(mil)	$16.32
Liability	(mil)	$0.80

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Provectus Pharmaceuticals, Inc. reported a net loss of $8,870,579 for the year ended December 31, 2006, lower than the net loss reported last year of $11,763,853. The Company has an accumulated depreciation of $35,200,405 as of December 31, 2006. The Company also used cash for operating activities of $4,274,776, higher than last year's cash usage of $3,783,586.

Intellectual Property: The Company holds 15 U.S. patents covering the technologies it has developed and are continuing to develop for the production of prescription drugs, medical devices and OTC pharmaceuticals. It continues to pursue patent applications on numerous other developments which are believed to be patentable. The Company considers the issued patents, pending patent applications and any patentable inventions it may develop to be extremely valuable assets of its business. The Company also owns the following trademarks: Xantryl™, Provecta™, GloveAid™, and Pure-ific™. It also owns the registered trademark PulseView®. [SEC Filing 10-KSB 03-22-07]

Description: The Company develops therapies designed to target and destroy breast cancer, liver cancer, and metastatic melanoma while eliminating side effects.

Officers: Timothy C. Scott (Pres.); H. Craig Dees (CEO); Peter R. Culpepper (CFO); Eric A. Wachter (VP)

Auditor: BDO Seidman, LLP

Securities: Common Stock-Symbol PVCT.OB; OTC BB;
45,450,619 common shares outstanding as of March 21, 2007.

Return to top

Prospector Profile 07.0530

QPC Lasers, Inc.

15632 Roxford Street
Sylmar, CA 91342
(818) 986-0000

NAICS		334413
Employees		42
Revenue	(mil)	$3.07
Income	(mil)	($18.69)
Assets	(mil)	$7.44
Liability	(mil)	$8.67

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Weinberg and Company, P.A expressed doubt on QPC Lasers, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. It has incurred a net loss of $18,692,607 and used $8,219,053 of cash in operations for the year ended December 31, 2006. The Company has a stockholders' deficiency of $1,231,330 as of December 31, 2006.

Intellectual Property: The Company has been granted 5 patents and has 10 patents pending. These patents cover a suite of different laser-related technologies and are related to process, performance characteristics and design. The Company has applied for patents in the key markets of North America, Asia and Europe, and has been granted trade secret protection, where appropriate. The Company believes that its products would be very difficult to reverse engineer and replicate with precision due to their complex nature. [SEC Filing 10-KSB 03-20-07]

Description: The Company engages in the design, development, manufacture, and commercialization of semiconductor lasers for the industrial, defense, and medical markets.

Officers: Jeffrey Ungar (Pres., CEO & Dir.); Gen. Merrill McPeak (Vice Chair); George Lintz (COO, CFO & Dir.); Israel Ury, Ph.D. (Dir.); Robert Adams (Dir.)

Auditor: Weinberg and Company, P.A

Securities: Common Stock-Symbol QPCI.OB; OTC BB;
38,559,283 common shares outstanding as of March 6, 2007.

Return to top

Prospector Profile 07.0531

Raptor Networks Technology, Inc.

1241 East Dyer Road, Suite 150
Santa Ana, CA 92705
(949) 623-9300

NAICS		334419
Employees		26
Revenue	(mil)	$0.85
Income	(mil)	($17.10)
Assets	(mil)	$5.09
Liability	(mil)	$19.43

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Comiskey & Company raised substantial doubt about Raptor Networks Technology, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor notes that the Company has sustained accumulated losses from operations totaling more than $58,500,000 at December 31, 2006 and has had no significant sales of its products to date.

Intellectual Property: The Company has eight U.S. patent applications pending, with broad claim sets covering numerous aspects of its Ethernet Distributed Switch Fabrics. The Company also has applications pending in Europe and Japan. [SEC Filing 10-K 03-20-07]

Description: The Company engages in the design, production, sale, and service of network switching technologies applied to inter-networking systems, operating in new and existing government and private sector applications worldwide.

Officers: Thomas M. Wittenschlaeger (Chair, Pres. & CEO); Bob van Leyen (Sec. & CFO); Ken Bramlett (Dir.); Larry L. Enterline (Dir.); Albert Wong (Dir.)

Auditor: Comiskey & Company

Securities: Common Stock-Symbol RPTN.OB; OTC BB;
54,885,863 common shares outstanding as of March 12, 2007.

Return to top

Prospector Profile 07.0532

Raser Technologies, Inc.

5152 North Edgewood Drive, Suite 375
Provo, UT 84604
(801) 765-1200

NAICS		334513
Employees		29
Revenue	(mil)	$0.12
Income	(mil)	($18.49)
Assets	(mil)	$11.41
Liability	(mil)	$0.70

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Raser Technologies, Inc. reported a net loss of $18,488,936 for fiscal year 2006, higher than the reported net loss of $8,932,816 in 2005 and $6,976,075 in 2004. As a result of its recurring losses, the Company has a total accumulated deficit of $35,473,648 as of December 31, 2006.

Intellectual Property: The Company's patented and patent pending technologies and related intellectual property are critical to its success. The Company relies on a combination of laws and contractual restrictions with employees, customers, suppliers, affiliates and others to establish and protect proprietary rights. The U.S. Patent and Trademark Office has issued six patents to the Company for resonant motors (U.S. Patent No's. 6,847,186 and 7,034,498); electromagnetic motors (U.S. Patent No. 7,034,499); motor controllers (U.S. Patent No. 7,026,785); pancake motors (U.S. Patent No. 7,116,029); and hydrodynamic slip rings (U.S. Patent No. 7,019,431). In addition, the Company has eight U.S. and five international patent applications which further define and develop the concepts of its core Symetron™ technologies. The Company licensed the heat transfer technology license from a third-party licensor. The license gives the Company certain rights to certain patented technologies. Five U.S. patents have been issued to the licensor, and one is pending, protecting these technologies. [SEC Filing 10-KSB 03-20-07]

Description: The Company is engaged in technology licensing focused on improving the efficiency of rotating electromagnetic and heat transfer applications within the transportation, industrial and power generation markets.

Officers: Kraig T. Higginson (Chair); Patrick Schwartz (Pres.); Brent M. Cook (CEO & Dir.); Lee A. Daniels (Dir.); James A. Herickhoff (Dir.); Alan G. Perriton (Dir.); Reynold Roeder (Dir.); Barry Markowitz (Dir.); Timothy D. Fehr (Dir.)

Auditor: Hein & Associates LLP

Securities: Common Stock-Symbol RSTG.OB; OTC BB;
51,436,212 common shares outstanding as of March 15, 2007.

Return to top

Prospector Profile 07.0533

Remington Arms Company, Inc.

870 Remington Drive
Madison, NC 27025
(336) 548-8700

NAICS		332994
Employees		2,150
Revenue	(mil)	$446.00
Income	(mil)	$0.30
Assets	(mil)	$371.30
Liability	(mil)	$381.50

(for the year ended 12/31/2006)

Category: Low Rating

Event: Standard & Poor's Rating's Services placed its Remington Arms Co., Inc.'s ratings, including the Company's 'CCC+' corporate credit rating, on CreditWatch with positive implications. Standard & Poor's rating action comes after the Company announced that an affiliate of Cerberus Capital Management LP would acquire the Company for about $370 million.

Intellectual Property: The Company's operations are not dependent upon any single trademark other than the Remington word mark and the Remington logo mark. Some of the other trademarks are nonetheless identified with and important to the sale of its products. The Company's business is not dependent to a material degree on patents, copyrights, or trade secrets. The Company does not believe that the expiration of any of its patents will have a material adverse effect on its financial condition or results of operations. In June 2000, the Company formed RA Brands, to which Remington transferred ownership of all of its patents, trademarks and copyrights. RA Brands owns all of the trademarks and licenses them to Remington at an arm's-length royalty rate. [SEC Filing 10-K 04-02-07]

Description: The Company designs, manufactures and markets a line of sporting goods for the hunting and shooting market under the Remington™ brand name. It also designs, manufactures and markets products with law enforcement, military and government applications.

Officers: Leon J. Hendrix, Jr. (Chair); Thomas L. Millner (Pres., CEO, & Dir.); Mark A. Little (EVP & Chief Admin. Officer); Stephen P. Jackson, Jr. (SVP, CFO, Treas., & Sec.); Paul L. Cahan (SVP-Eng. & Mfg.); B. Charles Ames (Dir.); Michael G. Babiarzi (Dir.); Bobby R. Brown (Dir.); Richard A. Gilleland (Dir.); Richard E. Heckert (Dir.); Hubbard C. Howe (Dir.); Thomas E. Ireland (Dir.); Thomas F. L'Esperance (Dir.); H. Norman Schwarzkopf (Dir.); Stephen C. Sherrill (Dir.)

Auditor: Grant Thornton LLP

Securities: 1,000 common shares outstanding as of March 27, 2007.
10.5% senior subordinated notes due 2011

Return to top

Prospector Profile 07.0534

Sabre Holdings Corporation
3150 Sabre Drive
Southlake, TX 76092
(682) 605-1000

NAICS		561510
Employees		9,000
Revenue	(mil)	$2,823.80
Income	(mil)	$155.64
Assets	(mil)	$4,282.42
Liability	(mil)	$2,359.06

(for the year ended 12/31/2006)

Category: Low Rating

Event: Moody's Investors Service downgraded the ratings of Sabre Holdings Corp.'s $400 million senior unsecured notes due August 2011 and $400 million senior unsecured notes due March 2016 to 'Caa1' from 'Baa3'. The rating outlook is stable. Moody's said that the downgrades reflect the Company's significant increase in financial leverage following the March 30, 2006 closing of the Company's acquisition by Silver Lake Partners and Texas Pacific Group.

Intellectual Property: The Company uses software, business processes and other proprietary information to carry out its business. These assets and related patents, copyrights, trade secrets, trademarks and other intellectual property rights are significant assets of its business. The Company relies on a combination of patent, copyright, trade secret and trademark laws, confidentiality procedures and contractual provisions to protect these assets. The Company seeks patent protection on key technology and business processes of its business. Its software and related documentation are also protected under trade secret and copyright laws. The Company also seeks statutory and common-law protection of trademarks.. [SEC Filing 10-K 02-23-07]

Description: The Company, through its subsidiary, Sabre, Inc., merchandises and retails travel products and provides distribution and technology solutions for the travel industry through Travelocity, Sabre Travel Network, and Sabre Airline Solutions.

Officers: Michael S. Gilliland (Chair & CEO); Jeffery M. Jackson (EVP, CFO, & Treas.); David Schwarte (EVP & Gen. Counsel); Michelle Peluso (EVP); Thomas Klein (EVP); Royce S. Caldwell (Dir.); Christopher J. Fraleigh (Dir.); Richard G. Lindner (Dir.); Glenn W. Marschel, Jr. (Dir.); Bob L. Martin (Dir.); Pamela B. Strobel (Dir.); Mary Alice Taylor (Dir.); Richard L. Thomas (Dir.); Ronald V. Waters III (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol TSG; NYSE;
133,799,727 common shares outstanding as of February 20, 2007.
6.35% senior unsecured notes due March 15, 2016; 7.35% senior unsecured notes due August 1, 2011.

Return to top

Prospector Profile 07.0535

SatCon Technology Corporation

27 Drydock Avenue
Boston, MA 02210
(617) 897-2400

NAICS		334413
Employees		261
Revenue	(mil)	$33.76
Income	(mil)	($19.78)
Assets	(mil)	$30.58
Liability	(mil)	$33.05

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Vitale, Caturano & Co. Ltd. raised substantial doubt about the ability of SatCon Technology Corp. to continue as a going concern after auditing the Company's financial statements for the years ended December 31, 2006, and 2005. The auditing firm pointed to the Company's recurring losses and negative cash flows.

Intellectual Property: The Company relies on a combination of patent, trademark, trade secret and copyright law and contract restrictions to protect the proprietary aspects of its technologies. It seeks to limit disclosure of intellectual property by requiring employees, consultants, and any third parties with access to proprietary information to execute confidentiality agreements and by restricting access to that information. As of December 31, 2006, the Company held approximately 68 U.S. patents and had 7 patent applications pending with the U.S. Patent and Trademark Office. It has also obtained corresponding patents in the rest of North America, Europe and Asia. In addition, the Company has a non-exclusive, royalty-free license for non-automotive applications for 38 other patents that were issued to its employees and subsequently assigned to DaimlerChrysler. In 1997, the Company granted Beacon Power Corporation a perpetual, worldwide, royalty-free, exclusive right and license to its flywheel technology for stationary, terrestrial applications. [SEC Filing 10-K 04-02-07]

Description: The Company designs and manufactures enabling technologies and products for electrical power conversion and control for high-performance, high-efficiency applications.

Officers: John M. Carroll (Chair); David B. Eisenhaure (Pres. & CEO); David E. O'Neil (VP-Fin. & Treas.); Daniel E. Gladkowski (VP-Admin.); Edward Wagner (VP-Eng.); Leo Casey (VP & Chief Tech. Officer); John W. Peacock (Chief Acctg. Officer & Controller); James L. Kirtley, Jr. (Dir.); Marshall J. Armstrong (Dir.); Daniel R. Dwight (Dir.); Joseph E. Levangie (Dir.); Andrew R. Muir (Dir.)

Auditor: Vitale, Caturano & Co. Ltd.

Securities: Common Stock Symbol SATC; NasdaqGM;
41,536,053 common shares outstanding as of March 1, 2007.

Return to top

Prospector Profile 07.0536

Securus Technologies, Inc.

14651 Dallas Parkway, Suite 600
Dallas, TX 75254
(972) 277-0300

NAICS		517110
Employees		591
Revenue	(mil)	$400.60
Income	(mil)	($20.12)
Assets	(mil)	$259.65
Liability	(mil)	$311.52

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Securus Technologies, Inc. posted a net loss of $20,119,000 on revenues of $400,600,000 for the year ended December 31, 2006, as compared with a net loss of $9,152,000 on revenues of $377,206,000 in 2005. As of December 31, 2006, the Company's balance sheet showed strained liquidity with $76,411,000 in total current assets and $90,924,000 in total current liabilities. The Company also reported $51,873,000 in stockholders' deficit and $86,019,000 in accumulated deficit.

Intellectual Property: The Company relies on a combination of patents, copyrights and trade secrets to establish and protect intellectual property rights. It considers any patents issued or licensed to be a significant factor to more effectively compete in the inmate calling industry. The Company believes that its intellectual property portfolio provides customers with leading edge technology that is recognized as technologically superior within the inmate telecommunications industry. The Company currently holds the broadest intellectual property portfolio in the industry, with 47 issued patents and more than 80 patent applications filed and/or in process. [SEC Filing 10-K 03-30-07]

Description: The Company, created from the merger of T-NETIX and Evercom, designs, implements, and maintains telecommunications systems and provides collect, pre-paid, and debit calling for inmates.

Officers: Richard Falcone (Chair); Robert Rae (EVP); Dennis Reinhold (VP, Gen. Counsel, & Sec.); John Viola (VP & Gen. Manager); Randy Hoffman (VP & Gen. Manager); Keith Kelson (CFO & Treas.); Sami Mnaymneh (Dir.); Tony Tamer (Dir.); Brian Schwartz (Dir.); Douglas Berman (Dir.); Lewis Schoenwetter (Dir.); Richard Cree (Dir.); Jack McCarthy (Dir.); James Neal Thomas (Dir.)

Auditor: KPMG LLP

Securities: 609,510.41 common shares outstanding as of December 31, 2006.
11% second-priority senior secured notes due 2011.

Return to top

Prospector Profile 07.0537

SPO Medical, Inc.
21860 Burbank Boulevard
Woodland Hills, CA 91367
(818) 888-4380

NAICS		541710
Employees		22
Revenue	(mil)	$3.71
Income	(mil)	($4.96)
Assets	(mil)	$2.79
Liability	(mil)	$3.69

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Brightman Almagor & Co. raised doubt about SPO Medical, Inc.'s ability to continue as a going concern due to its recurring losses from operations and shareholders' deficiency.

Intellectual Property: The Company currently relies on a combination of patent, trade secret, copyright and trademark law, as well as non-disclosure agreements and invention assignment agreements, to protect proprietary information. However, such methods may not afford complete protection and there can be no assurance that other competitors will not independently develop such processes, concepts, ideas and documentation. The Company holds three patents issued by the U.S. Patent and Trademark Office covering various aspects of its unique sensors for radiance-based diagnostics using pulse oximetry. [SEC Filing 10-K 03-20-07]

Description: The Company engages in the design, development, and marketing of non-invasive pulse oximetry technologies to monitor blood oxygen saturation and heart rate for medical, homecare, sports, and search and rescue markets.

Officers: Michael Braunold (Pres., CEO & Dir.); Richard H. Ryan (COO); Jeff Feuer (CFO); Israel Sarussi (CTO); Pauline Dorfman (Dir.); Sidney Braun (Dir.)

Auditor: Brightman Almagor & Co.

Securities: Common Stock-Symbol SPOM.PK; PNK;
19,335,525 common shares outstanding as of March 16, 2007.

Return to top

Prospector Profile 07.0538

Synthron, Inc. NAICS 313311
305 Amherst Road
Morganton, NC 28655
(828) 437-8611

Category: Chapter 7 Sale

Event: The Chapter 7 Trustee desires to liquidate some assets of Synthron, Inc. The assets include: raw material inventory and finshed chemical products and goods inventory in Riverside, Missouri and Lenoir, North Carolina; $190,000 in accounts receivable; trademark for “Synthron”; real property located at 305 Amherst Road, Morganton, North Carolina. Some of these assets have a value that is time sensitive in nature but there is no current bid deadline for these assets.

Intellectual Property: The Company has registered the trademark "Synthron" with the U.S. Patent & Trademark Office. [Website]

Description: The Company manufactures textile chemicals, water treatment chemicals and paper chemicals. It offers flow modifiers, catalysts, accelerators, surfactants and specialty additives for powder coatings. The Company filed for Chapter 11 protection on October 27, 2006 with the Bankruptcy Court for the District of Delaware, case number 06-11196, Judge Mary Walrath presiding. On March 19, 2007, the case was converted to Chapter 7 and Jeoffrey L. Burtch was appointed as Chapter 7 Trustee.

Attorneys: Donna L. Harris, Esq. of Cross & Simon LLC; Wilmington, DE; (302) 777-4200

Return to top

Prospector Profile 07.0539

Targeted Genetics Corporation

1100 Olive Way, Suite 100
Seattle, WA 98101
(206) 623-7612

NAICS		541710
Employees		70
Revenue	(mil)	$9.86
Income	(mil)	($33.99)
Assets	(mil)	$17.47
Liability	(mil)	$12.10

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Ernst & Young LLP raised substantial doubt about the ability of Targeted Genetics Corp. to continue as a going concern after auditing the Company's financial statements. The auditing firm pointed to the Company's recurring losses and negative cash flows from operations and limited working capital.

Intellectual Property: The Company has developed proprietary intellectual property, including methods of transferring genetic material into cells, processes to manufacture and purify gene therapeutic candidates, uses of AAV to deliver RNA therapeutics including RNAi and other proprietary technologies and processes. The Company has filed or licensed numerous patents or patent applications with the U.S. Patent and Trademark Office and foreign jurisdictions. It also relies on unpatented proprietary technology such as trade secrets, know-how and continuing technological innovations. The Company has licensed technology underlying several issued and pending patents, including two licenses to patents for the manufacture of AAV vectors and the use of AAV vectors for gene delivery. The exclusive license with Alkermes, Inc. provides the Company with rights to patents broadly covering a manufacturing method that is critical to making AAV-based products in a commercially viable, cost-effective manner. The license with the University of Pennsylvania provides the Company with licenses to a group of patents and patent applications with claims that cover AAV and adenoviral vector technologies including manufacturing methods. [SEC Filing 10-K 03-29-07]

Description: The Company researches and develops gene therapy products and technologies for the treatment of acquired and inherited diseases.

Officers: Jeremy L. Curnock Cook (Chair); H. Stewart Parker (Pres., CEO & Dir.); Barrie J. Carter (EVP & CSO); David J. Poston (VP, CFO & Treas.); Jack L. Bowman (Dir.); Joseph M. Davie (Dir.); Roger L. Hawley (Dir.); Nelson L. Levy (Dir.); Michael S. Perry (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol TGEN; NasdaqCM;
13,108,735 common shares outstanding as of March 16, 2007.

Return to top

Prospector Profile 07.0540

Thermadyne Holdings Corporation

16052 Swingley Ridge Road, Suite 300
Chesterfield, MO 63017
(636) 728-3000

NAICS		333512
Employees		2,885
Revenue	(mil)	$451.29
Income	(mil)	($23.05)
Assets	(mil)	$518.13
Liability	(mil)	$414.62

(for the year ended 12/31/2006)

Category: Low Rating

Event: Standard & Poor's Rating's Services placed its ratings on Thermadyne Holdings Corp., including the Company's 'CCC' corporate credit rating, on CreditWatch with positive implications. Standard & Poor's said that the Company previously delayed its fiscal year 2006 Form 10-K filing in order to allow its new independent auditor KPMG LLP enough time to review its financial statements and to obtain consent to include prior-year financial statement from the Company's previous independent auditor Ernst & Young LLP.

Intellectual Property: The Company's products are sold under a variety of trademarks and trade names. The Company owns trademark registrations or has filed trademark applications for all its trademarks and has registered all of its trade names that are material to the operation of its businesses. The Company also owns various patents and acquires licenses from owners of patents to apply such patents to its operations. [SEC Filing 10-K 03-30-07]

Description: Thermadyne Holdings Corp. designs and manufactures cutting and welding products that includes equipment, accessories and consumables.

Officers: Paul D. Melnuk (Chair & CEO); Steven A. Schumm (EVP, CFO, & Chief Admin. Officer); John A. Boisvertr (EVP); Terry Downes (EVP); Dennis G. Klanjscek (EVP); Martin Quinn (EVP); James B. Gamache (Dir.); Marnie S. Gordon (Dir.); John G. Johnson, Jr. (Dir.); Bradley G. Pattelli (Dir.); J. Joe Adorjan (Dir.); Andrew L. Berger (Dir.)

Auditor: KPMG LLP

Securities: Common Stock Symbol THMD.PK; Other OTC;
13,338,592 common shares outstanding as of March 28, 2007.
9-1/4% senior subordinated notes due February 1, 2014.

Return to top

Prospector Profile 07.0541

Thorium Power Limited

8300 Greensboro Drive, Suite 800
McLean, VA 22102
(703) 918-4904

NAICS		325188
Employees		5
Revenue	(mil)	$0.00
Income	(mil)	($11.71)
Assets	(mil)	$11.56
Liability	(mil)	$14.66

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Thorium Power Limited reported a net loss for the year ended December 31, 2006 of $11,708,328, higher than the reported net loss last year of $760,504. As a result of its recurring losses, the Company reported $27,177,989 in accumulated deficit and $3,094,326 in stockholder's deficit, compared to last year's accumulated deficit of $15,469,662 and stockholder's deficit of $757,103.

Intellectual Property: The Company's nuclear fuel technologies are protected by several U.S. and international patents. Its current patent portfolio is comprised of four U.S. patents and five international patents. [SEC Filing 10-KSB 03-20-07]

Description: The Company engages in the development, promotion, and marketing of nuclear fuel designs in the United States.

Officers: Seth Grae (Pres., CEO & Dir.); Larry Goldman (Treas. & CFO); Victor Alessi (Dir.); Jack Ladd (Dir.); Thomas Graham, Jr. (Dir.); Dan Magraw (Dir.)

Auditor: Child, Van Wagoner & Bradshaw, PLLC

Securities: Common Stock-Symbol THPW.OB; OTC BB;
297,221,116 common shares outstanding as of March 2, 2007.

Return to top

Prospector Profile 07.0542

Transmeta Corporation

3990 Freedom Circle
Santa Clara, CA 95054
(408) 919-3000

NAICS		344413
Employees		198
Revenue	(mil)	$48.55
Income	(mil)	($23.05)
Assets	(mil)	$56.73
Liability	(mil)	$14.05

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Burr, Pilger & Mayer LLP raised substantial doubt about the ability of Transmeta Corp. to continue as a going concern after auditing the Company's financial statements for the years ended December 31, 2006, and 2005. The auditing firm pointed to the Company's recurring losses and negative cash flows from operations. The Company posted a net loss of $23,498,000 on revenues of $48,550,000 for the year ended December 31, 2006, as compared with a net loss of $6,181,000 on revenues of $72,731,000 in 2005.

Intellectual Property: The Company relies on a combination of patents, copyrights, trademarks, trade secret laws and contractual restrictions on disclosure to protect intellectual property rights. Its intellectual property rights include numerous issued U.S. patents, with expiration dates ranging from 2012 to 2027. The Company also has a number of patent applications pending in the United States and in other countries. The Company also holds a number of trademarks, including Transmeta, Crusoe, Efficeon, LongRun, LongRun2, Code Morphing software, and AntiVirusNX. [SEC Filing 10-K 03-30-07]

Description: The Company develops and licenses innovative computing, microprocessor and semiconductor technologies and related intellectual property. The Company also designs, develops, and sells x86-compatible software-based microprocessors for computing platforms.

Officers: Murray A. Goldman (Chair); Lester M. Crudele (Pres. & CEO); John O'Hara Horsley (EVP, Gen. Counsel, & Sec.); Robert Bismuth (VP-Strategic Alliances); Ralph Harms (CFO); R. Hugh Barnes (Dir.); Robert V. Dickinson (Dir.); David R. Ditzel (Dir.); William P. Tai (Dir.); T. Peter Thomas (Dir.); Rick Timmins (Dir.)

Auditor: Burr, Pilger & Mayer LLP

Securities: Common Stock Symbol TMTA; NasdaqGM;
199,913,774 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0543

Viking Systems, Inc.

4350 La Jolla Village Dr., Suite 900
San Diego, CA 92122
(858) 431-4010

NAICS		334517
Employees		16
Revenue	(mil)	$5.62
Income	(mil)	($8.70)
Assets	(mil)	$3.46
Liability	(mil)	$6.68

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Squar Milner Peterson Miranda & Willamson LLP raised substantial doubt about the ability of Viking Systems, Inc. to continue as a going concern after auditing the Company's financial statements for the year ended Dec. 31, 2006. The auditing firm pointed to the Company's recurring losses from operations through Dec. 31, 2006, and working capital deficit at Dec. 31, 2006. The Company incurred a net loss of $8.7 million on net sales of $5.6 million for the year ended Dec. 31, 2006, compared with a net loss of $7.5 million on net sales of $3.8 million for the year ended Dec. 31, 2005.

Intellectual Property: Viking's technology base was built through internal research and development and by license and acquisition. Viking holds 14 patents, and non-exclusive license rights to 4 U.S. patents and 4 international patents. It also has exclusive license rights to 5 U.S. patents and 3 non-U.S. patents. In connection with the acquisition of the Vista Assets, the Company entered into a License Agreement pursuant to which Viking was granted certain license rights to technology under 22 patents. Upon execution of a Technology Transfer and Settlement Agreement in November 2006 with IVOW, ownership of 14 of the patents was transferred to the Company and the Company retained license rights to the remaining 8 patents. [SEC Filing 10-K 03-27-07]

Description: The Company engages in the design, manufacture, and marketing of three-dimensional and two-dimensional laparoscopic vision systems for use in minimally invasive surgical procedures.

Officers: Donald E. Tucker (Chair, Pres. & CEO); Gregory M. Decker (CFO); Joseph Warrino (Sec.); Lonna Williams (SVP); Daniel F. Crowley (Dir.); Nathan J. Harrison, M.D. (Dir.); Brian M. Miller (Dir.); Dr. Michael J. Manyak (Dir.)

Auditor: Squar Milner Peterson Miranda & Willamson LLP

Securities: Common Stock-Symbol VKSY.OB; OTC BB;
65,864,941 common shares outstanding as of March 23, 2007.

Return to top

Prospector Profile 07.0544

Web.com, Inc.

303 Peachtree Center Avenue, Suite 500
Atlanta, GA 30303
(404) 260-2477

NAICS		541511
Employees		259
Revenue	(mil)	$49.14
Income	(mil)	($13.72)
Assets	(mil)	$38.43
Liability	(mil)	$17.47

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Web.com, Inc. reported a net loss of $13.724 million on revenues of $49.140 million for the year ended December 31, 2006, compared to a net loss of $19.889 million on revenues of $88.608 million during the previous fiscal year. As a result of its recurring losses, the Company has an accumulated deficit of $312.554 million as of December 31, 2006.

Intellectual Property: Web.com relies on a combination of laws (including patent, copyright, trademark, service mark and trade secret laws) and contractual restrictions to establish and protect proprietary rights in its services. As of December 31, 2006, the Company owned 19 issued U.S. patents and several additional patent applications pending but not yet issued. In July 2006, the Company entered into a non-exclusive license agreement with Hostopia.com, Inc. that grants Hostopia rights to two of Web.com's patents over five years on a non-transferable basis. Web.com licenses, or leases from others, many technologies used in its services. [SEC Filing 10-K 03-20-07]

Description: The Company, together with its subsidiaries, provides Websites and Web services to small and medium-sized businesses in the United States.

Officers: Seymour Holtzman (Chair); Jeffrey M. Stibel (CEO); Gonzalo Troncoso (EVP & CFO); John B. Balousek (Dir.); John Patrick Crecine (Dir.); Alex Kazerani (Dir.); Robert T. Slezak (Dir.); Efrem Gerszberg (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol WWWW; NasdaqGM;
16,784,108 common shares outstanding as of February 28, 2007.

Return to top

Prospector Profile 07.0545

World Heart Corp.

7799 Pardee Lane
Oakland, CA 94621
(510) 563-5000

NAICS		334510
Employees		63
Revenue	(mil)	$8.62
Income	(mil)	($20.09)
Assets	(mil)	$20.50
Liability	(mil)	$5.79

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: PricewaterhouseCoopers LLP raised substantial doubt about the ability of World Heart Corporation to continue as a going concern due to its recurring losses. The Company incurred net losses of $20.1 million and $52.8 million for the years ended Dec. 31, 2006, and 2005, respectively.

Intellectual Property: The Company has been granted six active U.S. patents for the Novacor LVAS and its associated subsystems. A subset of these patents has also been filed and granted in the major European countries, in Canada and in Japan. To date, the Company has been granted two U.S. patents and two patent applications are pending for the Novacor II, and corresponding applications are also pending in Europe, Japan and Canada. The Transcutaneous Energy Transfer technology licensed to WorldHeart from the Ottawa Heart Institute, has been patented in the U.S., Canada and the U.K. WorldHeart holds various patents and licenses to patents related to the Levacor Rotary VAD and other potential future products. WorldHeart has ownership and/or exclusive licenses to 11 patents related to the Levacor implantable blood pump technology. In addition, two patents related to control of rotary blood pumps are non-exclusively licensed. The Company has a number of trademarks, and has federally registered several, including the WORLDHEART logo mark and the NOVACOR mark, the MEDQUEST mark and the AUTOME mark. Pending applications for registration of other marks include the HEARTQUEST mark, MAGLEV mark and the LEVACOR mark. [SEC Filing 10-K 03-29-07]

Description: The Company is a medical devices firm focused on the sales, production, support and development of pulsatile ventricular assist devices.

Officers: C. Ian Ross (Chair); Jal S. Jassawalla (Pres., CEO & Dir.); A. Richard Juelis (VP & CFO); John F. Carlson (Dir.); William C. Garriock (Dir.); Robert J. Majteles (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol WHRT; NasdaqNM;
115,072,749 common shares outstanding as of March 1, 2007.
3% unsecured convertible debentures due September 15, 2009.

Return to top

Prospector Profile 07.0546

Zi Corporation

840-7th Avenue SW, Suite 2100
Calgary, Alberta T2P 3G2
Canada
(403) 233-8875

NAICS 541511

Revenue	(mil)	$12.39
Income	(mil)	($10.99)
Assets	(mil)	$14.55
Liability	(mil)	$9.73

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Zi Corporation reported a fourth quarter net loss of $3 million for the period ended Dec. 31, 2006, compared to a net loss of $2.1 million in the same period of the prior year. The 2006 full year loss was $11 million, compared to a net loss of $5.3 million for fiscal 2005. At Dec. 31, 2006, the Company had an accumulated deficit of $108.6 million and used cash in operating activities of $7.4 million. Continuing operations are dependent on the Company achieving profitable operations and being able to raise additional capital to meet its obligations and repay liabilities arising from the normal operations when they come due.

Intellectual Property: On December 17, 1997, the Company acquired ownership rights to U.S. patent number 5,109,352 for a computer input system for Chinese and Japanese characters where the different strokes for composing the characters are classified into different groups, each identified by a code number. Taiwanese patent No. NI139820 and Chinese patent ZL99-1-00625.9 were issued to the Company, which protects the unique implementation of its Chinese language input technology on cellular phones and other wireless devices and, in particular, protect those combinations of elements. The Company was also granted an equivalent of this patent in Hong Kong as patent number HK1020216. The Compay also has 4 U.S. patents , which further strengthen its competitive position. [SEC Filing 10-K 04-02-07]

Description: The Company provides intelligent interfaces software products in Canada, the United States, Sweden, and China.

Officers: Milos Djokovic (Pres., CEO & Dir.); Blair Mullin (CFO); Derrick R. Armstrong (Sec.); H. Donald Hyde (Dir.); Michael E. Lobsinger (Dir.); Donald P. Moore (Dir.); Richard D. Tingle (Chair); Robert P. Stefanski (Dir.);

Auditor: Deloitte & Touche LLP

Securities: Common Stock-Symbol ZICA; NasdaqGM;
46,688,624 common shares outstanding as of December 31, 2006.

Return to top